• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States;
• provide models to assist Member States in developing their own mono- graphs or formularies for these... or other herbal medicines; and
• facilitate information exchange among Member States.
more
• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States;
• provide models to assist Member States in developing their own mono- graphs or formularies for these... or other herbal medicines; and
• facilitate information exchange among Member States.
more
• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States;
• provide models to assist Member States in developing their own mono- graphs or formularies for these... or other herbal medicines; and
• facilitate information exchange among Member States.
more
The manufacturing process is one of the key steps where quality control is required to ensure quality of medicinal products, including herbal medicines. Good manufacturing practices (GMP) is one of the most important tools for this measure.
6th edition, 2010. | Published in collaboration with World Health Organisation and Clinton Health Access Initiative.
The report provides a brief introduction to patents and licences and their effect on the market for antiretroviral (ARV) medicines. It gives an overview of the patent landscape with respect to a select number of ARV medicines in developing countries as of April 2014. The focus is primarily on those ...ARVs that are recommended by the World Health Organization (WHO) as well as new ARVs that have either recently obtained regulatory approval or are in phase III clinical trials.
more
procédures : guide méthodologique
La méningite est mortelle et débilitante ; elle frappe brutalement ; elle a de graves conséquences sanitaires, économiques et sociales et touche tous les âges de la vie dans tous les pays du monde. La méningite bactérienne peut être à l’origine d’épidémies, entraîner la mort dans les... 24 heures et un patient sur cinq peut rester handicapé à vie à la suite d’une infection. La plupart des cas et des décès dus à la méningite pourraient être évités par la vaccination mais les progrès obtenus pour la vaincre sont bien moins rapides que ceux réalisés contre d’autres maladies à prévention vaccinale.
more
Drug Distribution and Control: Preparation and Handling–Guidelines
Review 2008
a dernière mise à jour a été effectuée dans le livret de la PCIME en 2014, mais depuis lors, des mises à jour importantes ont été effectuées sur la prise en charge du jeune nourrisson malade (MJN) âgé de moins de 2 mois. Cette mise à jour 2019 de la section sur le jeune enfant malade Pri...se en charge du jeune enfant malade âgé de moins de 2 mois : IMCI chart booklet. remplace le IMCI chart booklet de 2014. Les nouvelles mises à jour reflètent les récentes lignes directrices sur la prise en charge des infections bactériennes graves possibles (IPSP) chez les jeunes nourrissons lorsque l'orientation vers un spécialiste n'est pas possible, publiées en 2015. Elles comprennent l'évaluation, la classification et l'orientation de la SYI avec PSBI ; et le traitement ambulatoire de la SYI avec infection locale ou respiration rapide (pneumonie) chez les nourrissons âgés de 7 à 59 jours. Les autres mises à jour comprennent : une nouvelle section sur la manière de réévaluer, de classer et de traiter la SYI avec PSBI lorsque l'orientation n'est pas possible dans les établissements de santé ambulatoires par des agents de santé formés à la PCIME ; des changements dans l'évaluation et la prise en charge des jeunes nourrissons pour l'infection par le VIH ; et l'identification des nourrissons de moins de 7 jours de qui ont besoin de soins kangourou.
more
It is Zika virus (ZIKV) that most often causes these neurological effects it appears to be the only arbovirus than can cause congenital malformations such as microcephaly. In any case, more scientific tests are needed to establish the causal relationship between the virus and this malformation (7-10...).
This document is a practical tool designed to help health workers improve clinical diagnosis and provide timely care for patients infected
with the dengue, chikungunya, or Zika virus. It is intended mainly for
health workers in primary care facilities where laboratory diagnosis of
arboviruses is not always available. However, this guide may also be
very useful in hospitals that provide second- and third-level care, as it
describes the clinical manifestations of each of the three most important
arboviral diseases currently found in the Region, the elements for
differential diagnosis, and their clinical behavior.
more
The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr...ess the emergency.
MAAP reviewed 819,584 AMR records from 2016-2019, from 205 laboratories across Burkina Faso, Cameroon, Eswatini, Gabon, Ghana, Kenya, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe. MAAP also reviewed data from 327 hospital and community pharmacies and 16 national-level AMC datasets.
more
The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr...ess the emergency.
MAAP reviewed 819,584 AMR records from 2016-2019, from 205 laboratories across Burkina Faso, Cameroon, Eswatini, Gabon, Ghana, Kenya, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe. MAAP also reviewed data from 327 hospital and community pharmacies and 16 national-level AMC datasets.
more